phrykt

Stoke Therapeutics, Inc. (STOK): who owns it and who trades it

As of Nov 16, 2026, STOK insiders reported 79 open-market sales worth $7.9M and no purchases in the last 12 months, with 81% of the sale value made under pre-set 10b5-1 plans. The largest seller was Adrian R. Krainer (Director), with $2.8M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Stoke Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns STOK

199 funds and institutions reported STOK shares worth $2.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.9.4%
Rtw Investments, LP9.0%
FMR LLC (Fidelity)8.5%
Lynx1 Capital Management LP6.5%
Redmile Group, LLC6.3%
Wellington Management Group LLP5.7%
Morgan Stanley5.5%
Baker Bros. Advisors LP5.4%
Toronto Dominion Bank5.1%
State Street Corp4.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.88M9.44%$192M+9%
Rtw Investments, LP5.62M9.03%$184MNo change
FMR LLC (Fidelity)5.31M8.53%$174M-1%
Lynx1 Capital Management LP4.04M6.48%$132M-15%
Redmile Group, LLC3.95M6.34%$129M-5%
Wellington Management Group LLP3.52M5.65%$115M+14%
Morgan Stanley3.45M5.54%$113M+1%
Baker Bros. Advisors LP3.34M5.36%$109MNo change
Toronto Dominion Bank3.17M5.10%$104MNo change
State Street Corp2.85M4.58%$93.3M+25%
T. Rowe Price Associates2.66M4.27%$87.1M+38%
Vanguard Capital Management LLC2.59M4.15%$84.6M+10%
Bvf Inc2.55M4.09%$83.4MNo change
T. Rowe Price Investment Management, Inc.2.42M3.88%$79M+863%
Assenagon Asset Management S.A.2.26M3.62%$73.8M+149%
Siren, L.L.C.2.00M3.20%$65.3MNo change
Deerfield Management Company, L.P.1.82M2.93%$59.7MNo change
Jupiter Topco LLC1.81M2.91%$59.4M–
California State Teachers Retirement System1.64M2.63%$50.1M+3079%
Geode Capital Management, LLC1.52M2.45%$49.9M+15%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, STOK insiders reported $0 of open-market purchases and $7.9M of sales. 81% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$7.9M
79 trades, 8 people
Sales under a 10b5-1 plan
81%
Share of sale value
Latest trade
Nov 2, 2026
Filed Nov 4, 2026

Purchases and sales by month

$3.1M$3.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 2, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan6,995$26.38$185KForm 4
Nov 2, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan200$26.99$5.4KForm 4
Oct 2, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale plan627$26.33$16.5KForm 4
Oct 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan1,051$26.16$27.5KForm 4
Sep 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan1,600$31.06$49.7KForm 4
Sep 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan3,945$30.51$120KForm 4
Aug 18, 2026Barry TichoCHIEF MEDICAL OFFICERSale242$32.47$7.9KForm 4
Aug 18, 2026Barry TichoCHIEF MEDICAL OFFICERSale4,525$32.01$145KForm 4
Aug 18, 2026Edward M. MD KayeDirectorSale637$32.47$20.7KForm 4
Aug 18, 2026Edward M. MD KayeDirectorSale11,930$32.01$382KForm 4
Aug 18, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale145$32.47$4.7KForm 4
Aug 18, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale2,716$32.01$86.9KForm 4
Aug 3, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan5,907$28.95$171KForm 4
Aug 3, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan1,269$29.45$37.4KForm 4
Jul 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan500$33.27$16.6KForm 4
Jul 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan6,728$32.62$219KForm 4
Jun 16, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale plan1,457$29.95$43.6KForm 4
Jun 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan1,795$30.58$54.9KForm 4
May 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan2,243$32.79$73.5KForm 4
Apr 1, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan1,838$32.66$60KForm 4
Mar 20, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale plan8,692$33.64$292KForm 4
Mar 20, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale plan601$34.41$20.7KForm 4
Mar 19, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan1,461$29.99$43.8KForm 4
Mar 18, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan6,100$31.28$191KForm 4
Mar 18, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan103$32.85$3.4KForm 4
Mar 18, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan483$31.79$15.4KForm 4
Mar 18, 2026Thomas LeggettCFOSale37$32.85$1.2KForm 4
Mar 18, 2026Thomas LeggettCFOSale172$31.79$5.5KForm 4
Mar 18, 2026Thomas LeggettCFOSale2,173$31.28$68KForm 4
Mar 18, 2026Jason HoittChief Patient OfficerSale139$31.79$4.4KForm 4
Mar 18, 2026Jason HoittChief Patient OfficerSale1,762$31.28$55.1KForm 4
Mar 18, 2026Jason HoittChief Patient OfficerSale30$32.85$986Form 4
Mar 18, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale4,222$31.28$132KForm 4
Mar 18, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale72$32.85$2.4KForm 4
Mar 18, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale334$31.79$10.6KForm 4
Mar 17, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan3,577$32.74$117KForm 4
Mar 17, 2026Barry TichoCHIEF MEDICAL OFFICERSale plan2,587$33.38$86.4KForm 4
Mar 17, 2026Thomas LeggettCFOSale922$33.38$30.8KForm 4
Mar 17, 2026Thomas LeggettCFOSale1,274$32.74$41.7KForm 4
Mar 17, 2026Jason HoittChief Patient OfficerSale748$33.38$25KForm 4
Mar 17, 2026Jason HoittChief Patient OfficerSale1,033$32.74$33.8KForm 4
Mar 17, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale2,476$32.74$81.1KForm 4
Mar 17, 2026Jonathan AllanGENERAL COUNSEL & CORP SSale1,791$33.38$59.8KForm 4
Mar 13, 2026Arthur A LevinDirectorSale plan605$36.80$22.3KForm 4
Mar 10, 2026Arthur TzianabosChairSale plan4,355$40.00$174KForm 4
Mar 10, 2026Adrian R. KrainerDirectorSale plan33,243$39.74$1.3MForm 4
Mar 2, 2026Adrian R. KrainerDirectorSale plan7,229$39.66$287KForm 4
Dec 8, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale plan2,678$32.61$87.3KForm 4
Dec 8, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale plan1,300$31.60$41.1KForm 4
Dec 8, 2025Edward M. MD KayeDirectorSale plan8,274$32.52$269KForm 4
Dec 8, 2025Edward M. MD KayeDirectorSale plan3,825$31.44$120KForm 4
Dec 8, 2025Edward M. MD KayeDirectorSale plan1,331$33.10$44.1KForm 4
Dec 5, 2025Barry TichoCHIEF MEDICAL OFFICERSale plan1,673$31.33$52.4KForm 4
Dec 5, 2025Barry TichoCHIEF MEDICAL OFFICERSale plan1,989$31.35$62.4KForm 4
Dec 5, 2025Edward M. MD KayeDirectorSale plan500$31.85$15.9KForm 4
Dec 5, 2025Edward M. MD KayeDirectorSale plan6,367$31.33$199KForm 4
Dec 5, 2025Edward M. MD KayeDirectorSale plan1,681$31.15$52.4KForm 4
Dec 5, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale plan2,344$31.76$74.4KForm 4
Dec 5, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale plan1,004$31.33$31.5KForm 4
Dec 5, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale plan5,437$31.08$169KForm 4
Dec 4, 2025Barry TichoCHIEF MEDICAL OFFICERSale plan323$31.32$10.1KForm 4
Dec 4, 2025Barry TichoCHIEF MEDICAL OFFICERSale plan1,373$30.76$42.2KForm 4
Dec 4, 2025Edward M. MD KayeDirectorSale plan5,222$30.76$161KForm 4
Dec 4, 2025Edward M. MD KayeDirectorSale plan1,231$31.32$38.6KForm 4
Dec 4, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale plan824$30.76$25.3KForm 4
Dec 4, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale plan194$31.32$6.1KForm 4
Dec 3, 2025Barry TichoCHIEF MEDICAL OFFICERSale789$30.34$23.9KForm 4
Dec 3, 2025Barry TichoCHIEF MEDICAL OFFICERSale1,225$30.85$37.8KForm 4
Dec 3, 2025Edward M. MD KayeDirectorSale419$30.34$12.7KForm 4
Dec 3, 2025Edward M. MD KayeDirectorSale651$30.85$20.1KForm 4
Dec 3, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale1,394$30.85$43KForm 4
Dec 3, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale898$30.34$27.2KForm 4
Dec 2, 2025Barry TichoCHIEF MEDICAL OFFICERSale1,244$29.56$36.8KForm 4
Dec 2, 2025Barry TichoCHIEF MEDICAL OFFICERSale762$30.14$23KForm 4
Dec 2, 2025Edward M. MD KayeDirectorSale405$30.14$12.2KForm 4
Dec 2, 2025Edward M. MD KayeDirectorSale661$29.56$19.5KForm 4
Dec 2, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale868$30.14$26.2KForm 4
Dec 2, 2025Jonathan AllanGENERAL COUNSEL & CORP SSale1,416$29.56$41.9KForm 4
Nov 24, 2025Adrian R. KrainerDirectorSale plan40,472$29.72$1.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Adrian R. KrainerDirector–$2.8MMar 10, 2026
Barry TichoCHIEF MEDICAL OFFICER–$1.9MNov 2, 2026
Edward M. MD KayeDirector–$1.4MAug 18, 2026
Jonathan AllanGENERAL COUNSEL & CORP SEC–$1.3MOct 2, 2026
Arthur TzianabosInterim Executive Chair, Director–$174KMar 10, 2026
Thomas LeggettChief Financial Officer–$147KMar 18, 2026
Jason HoittChief Patient Officer–$119KMar 18, 2026
Arthur A LevinDirector–$22.3KMar 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

STOK short interest

High short interest. 16.4% of STOK shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 17%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.72M STOK shares were sold short, 16.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.59M shares, buying them all back would take about 6.8 trading days (days to cover).

Shares short, % of all shares

16.4%May 15Oct 3026.6%

Days to cover

6.8May 15Oct 3030.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.72M16.39%+5%1.59M6.8
Oct 15, 202610.26M15.90%-11%831,75712.3
Sep 30, 202611.51M17.83%+3%1.13M10.2
Sep 15, 202611.15M17.28%-0%643,98417.3
Aug 31, 202611.20M17.36%-14%944,06511.9
Aug 14, 202612.98M20.11%-18%1.02M12.7
Jul 31, 202615.81M24.50%+1%571,43527.7
Jul 15, 202615.69M25.20%+13%757,04020.7
Jun 30, 202613.91M22.33%+19%1.39M10.0
Jun 15, 202611.72M18.82%+4%523,96622.4
May 29, 202611.23M18.03%-13%586,91019.1
May 15, 202612.92M20.74%-1%521,88824.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Stoke Therapeutics company events

Stoke Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, auditor). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Sep 25, 2026LeadershipEdward M. Kaye, M.D. notified the Board of Directors of Stoke Therapeutics, Inc. of his intent to resign as a Class III director of the Board, and as a member of the Research and Development Committee of the Board, effective September 23, 2026. Filing
  3. Aug 3, 2026AnnouncementAs previously disclosed, on May 20, 2022, Stoke Therapeutics, Inc., a Delaware corporation, entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., pursuant to which the Company may offer and sell shares of common stock of the Company, par value $0.0001 per share… Filing
  4. Aug 3, 2026ResultsReleased financial results. Filing
  5. Jun 30, 2026AnnouncementAs noted in the Press Release, enrollment of 162 patients into the EMPEROR study has now completed in the planned primary analysis population across the U.S., U.K., and Japan. Filing
  6. Jun 4, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 7, 2026LeadershipThe Board of Directors of Stoke Therapeutics, Inc., increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effective… Filing
  9. Mar 27, 2026AuditorChanges in Registrant’s Certifying Accountants. Filing
  10. Mar 3, 2026LeadershipThe Board of Directors of Stoke Therapeutics, Inc. approved a discretionary bonus of $697,125 for Ian F. Smith, the Company’s Chief Executive Officer. Filing
  11. Jan 26, 2026AgreementStoke Therapeutics, Inc. entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts, in order to expand its office and laboratory space. Filing
  12. Jan 12, 2026AnnouncementThe Press Release provides an update related to the design of the Company’s Phase 3 clinical trial of zorevunersen, including the following: Phase 3 Study of Zorevunersen • The Company expects to complete enrollment of 150 patients in the second quarter of 2026, with a data readout in mid-2027 that… Filing
  13. Dec 5, 2025AnnouncementAs noted in the Press Release, the Company and Biogen presented data at the AES Annual Meeting that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome, including the following: Propensity Score Weighted… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Stoke Therapeutics financials

Famous investors that hold STOK

2 of the 50 well-known investors we track reported holding STOK in their latest 13F filing. The largest position is Ken Griffin's, worth $14.2M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026547,477$14.2M0.0%+12%
Israel Englander · Millennium ManagementQ3 2026515,828$13.4M0.0%+98%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named STOK in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Baker Bros. Advisors LP13G/A4.7%
Nov 16, 2026RTW Investments, LP13G/A9.9%
Nov 16, 2026Wellington Management Group LLP13G/A7.3%
Nov 16, 2026Baker Bros. Advisors LP13G/A4.7%
Nov 16, 2026RTW Investments, LP13G/A9.9%
Nov 16, 2026Wellington Management Group LLP13G/A7.3%
Nov 13, 2026Morgan Stanley13G/A4.9%
Nov 13, 2026Morgan Stanley13G/A4.9%
Nov 5, 2026FMR LLC13G/A7.5%
Nov 5, 2026FMR LLC13G/A7.5%

Questions about Stoke Therapeutics, Inc. (STOK) stock

Who owns the most STOK stock?

The largest reported owner of Stoke Therapeutics, Inc. (STOK) is BlackRock, Inc., with 9.4% of the company. In total, 199 funds and institutions reported holding STOK at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are STOK insiders buying or selling?

In the last 12 months, STOK insiders reported no open-market purchases and 79 sales worth $7.9M. The latest trade was on Nov 2, 2026. See every trade.

What is the short interest in STOK?

As of Oct 30, 2026, 10.72M STOK shares were sold short, 16.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.59M shares, buying them all back would take about 6.8 trading days (days to cover). See the history.

Which famous investors hold STOK?

2 of the 50 well-known investors we track reported STOK in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $14.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.